- Home
- HNST vs AUTL Comparison
HNST vs AUTL Comparison
Compare HNST & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNST
- AUTL
- Stock Information
- Founded
- HNST 2012
- AUTL 2014
- Country
- HNST United States
- AUTL United Kingdom
- Employees
- HNST N/A
- AUTL N/A
- Industry
- HNST Catalog/Specialty Distribution
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HNST Consumer Discretionary
- AUTL Health Care
- Exchange
- HNST Nasdaq
- AUTL Nasdaq
- Market Cap
- HNST 639.1M
- AUTL 609.4M
- IPO Year
- HNST 2021
- AUTL 2018
- Fundamental
- Price
- HNST $6.58
- AUTL $2.22
- Analyst Decision
- HNST Buy
- AUTL Strong Buy
- Analyst Count
- HNST 6
- AUTL 3
- Target Price
- HNST $6.71
- AUTL $10.20
- AVG Volume (30 Days)
- HNST 2.5M
- AUTL 1.4M
- Earning Date
- HNST 03-05-2025
- AUTL 03-13-2025
- Dividend Yield
- HNST N/A
- AUTL N/A
- EPS Growth
- HNST N/A
- AUTL N/A
- EPS
- HNST N/A
- AUTL N/A
- Revenue
- HNST $368,767,000.00
- AUTL $10,091,000.00
- Revenue This Year
- HNST $11.05
- AUTL $851.83
- Revenue Next Year
- HNST $5.78
- AUTL $264.18
- P/E Ratio
- HNST N/A
- AUTL N/A
- Revenue Growth
- HNST 9.77
- AUTL 82.71
- 52 Week Low
- HNST $2.40
- AUTL $2.07
- 52 Week High
- HNST $8.97
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- HNST 49.50
- AUTL 38.18
- Support Level
- HNST $5.63
- AUTL $2.18
- Resistance Level
- HNST $6.71
- AUTL $2.38
- Average True Range (ATR)
- HNST 0.33
- AUTL 0.16
- MACD
- HNST -0.04
- AUTL 0.01
- Stochastic Oscillator
- HNST 63.33
- AUTL 7.94
About HNST The Honest Company Inc.
The Honest Co Inc is a digitally-native consumer products company to makes purpose-driven consumer products designed for all people. It is an omnichannel brand, ensuring its products are available wherever its consumers shop through the company's Retail and Digital channels. It has three product categories namely; Diapers and Wipes, Skin and Personal Care, and Household and Wellness, out of which the majority of its revenue is generated from the sale of diapers and wipes. The company operates only in the United States.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.